MLV

MLV is out with its report today on Peregrine Pharmaceuticals (NASDAQ: PPHM), lowering its PT from $10 to $8.50. In a note to clients, MLV writes, "In our view, Peregrine has made considerable progress in advancing its pipeline and several major catalysts are approaching, however delays have led...

According to MLV, SuperGen (NASDAQ: SUPG) and its U.S. collaborative partner Eisai announced that the FDA has accepted the supplemental New Drug Application (sNDA) of Dacogen for the treatment of acute myeloid leukemia. MLV said that it expects the FDA to assign a PDUFA date of next March, 2012,...

According to MLV, Vivus (NASDAQ: VVUS) Buy rating is reiterated. MLV said that it reiterates its BUY rating and $16 price target. “As a reminder, VVUS plans to conduct a retrospective fetal outcomes study using existing US electronic healthcare databases. The FORTRESS study will analyze the...